JP2014503596A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2014503596A5 JP2014503596A5 JP2013551380A JP2013551380A JP2014503596A5 JP 2014503596 A5 JP2014503596 A5 JP 2014503596A5 JP 2013551380 A JP2013551380 A JP 2013551380A JP 2013551380 A JP2013551380 A JP 2013551380A JP 2014503596 A5 JP2014503596 A5 JP 2014503596A5
- Authority
- JP
- Japan
- Prior art keywords
- disorder
- aminopyridine
- therapeutic agent
- agent according
- pharmaceutically acceptable
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Withdrawn
Links
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201161437558P | 2011-01-28 | 2011-01-28 | |
| US61/437,558 | 2011-01-28 | ||
| PCT/US2012/022960 WO2012103471A1 (en) | 2011-01-28 | 2012-01-27 | Use of potassium channel blockers to treat cerebral palsy |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2016132185A Division JP2016222685A (ja) | 2011-01-28 | 2016-07-04 | 脳性麻痺を治療するためのカリウムチャネル遮断薬の使用 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2014503596A JP2014503596A (ja) | 2014-02-13 |
| JP2014503596A5 true JP2014503596A5 (enExample) | 2015-03-19 |
Family
ID=45567148
Family Applications (3)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2013551380A Withdrawn JP2014503596A (ja) | 2011-01-28 | 2012-01-27 | 脳性麻痺を治療するためのカリウムチャネル遮断薬の使用 |
| JP2016132185A Pending JP2016222685A (ja) | 2011-01-28 | 2016-07-04 | 脳性麻痺を治療するためのカリウムチャネル遮断薬の使用 |
| JP2018136369A Pending JP2018197242A (ja) | 2011-01-28 | 2018-07-20 | 脳性麻痺を治療するためのカリウムチャネル遮断薬の使用 |
Family Applications After (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2016132185A Pending JP2016222685A (ja) | 2011-01-28 | 2016-07-04 | 脳性麻痺を治療するためのカリウムチャネル遮断薬の使用 |
| JP2018136369A Pending JP2018197242A (ja) | 2011-01-28 | 2018-07-20 | 脳性麻痺を治療するためのカリウムチャネル遮断薬の使用 |
Country Status (7)
| Country | Link |
|---|---|
| US (1) | US20130030025A1 (enExample) |
| EP (2) | EP2667869A1 (enExample) |
| JP (3) | JP2014503596A (enExample) |
| AU (1) | AU2012211101B2 (enExample) |
| BR (1) | BR112013019265A2 (enExample) |
| CA (1) | CA2825810A1 (enExample) |
| WO (1) | WO2012103471A1 (enExample) |
Families Citing this family (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US9205577B2 (en) * | 2010-02-05 | 2015-12-08 | Allergan, Inc. | Porogen compositions, methods of making and uses |
| US9138309B2 (en) | 2010-02-05 | 2015-09-22 | Allergan, Inc. | Porous materials, methods of making and uses |
| US11202853B2 (en) * | 2010-05-11 | 2021-12-21 | Allergan, Inc. | Porogen compositions, methods of making and uses |
| US10793893B2 (en) | 2011-06-30 | 2020-10-06 | Serb Sa | Methods of administering 3,4-diaminopyridine |
| TWI592156B (zh) * | 2011-10-04 | 2017-07-21 | 艾可達醫療公司 | 使用胺基吡啶以治療與中風有關之感覺動作損傷之方法 |
| CA2909527A1 (en) * | 2013-04-15 | 2014-10-23 | Acorda Therapeutics, Inc. | Methods for treating sensorimotor impairments associated with certain types of stroke using aminopyridines |
| WO2017168333A1 (en) * | 2016-04-02 | 2017-10-05 | Shilpa Medicare Limited | Amifampridine dihydrochloride |
| EP3727587A4 (en) * | 2017-12-22 | 2022-02-23 | Massachusetts Institute Of Technology | COMPOSITIONS AND METHODS FOR THERAPY OF WILLIAMS SYNDROME (WS) |
| WO2020163495A1 (en) * | 2019-02-06 | 2020-08-13 | Allergan, Inc. | Combination therapy using clostridial toxin derivative and at least one chemical depolarizing agent |
| CA3176457A1 (en) * | 2020-04-08 | 2021-10-14 | The Trustees Of Indiana University | Therapeutic strategies to manage facial contractures post injury |
Family Cites Families (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA2085785C (en) * | 1992-12-18 | 2005-03-15 | Robert R. Hansebout | The use of 4-aminopyridine in the treatment of a neurological condition |
| US5952357A (en) * | 1993-12-23 | 1999-09-14 | Cornell Research Foundation, Inc. | Treating diseases of the anterior horn cells |
| GB0119435D0 (en) * | 2001-02-15 | 2001-10-03 | Aventis Pharm Prod Inc | Method of treating of demyelinating diseases or conditions |
| US8007826B2 (en) | 2003-12-11 | 2011-08-30 | Acorda Therapeutics, Inc. | Sustained release aminopyridine composition |
| US8354437B2 (en) | 2004-04-09 | 2013-01-15 | Acorda Therapeutics, Inc. | Method of using sustained release aminopyridine compositions |
| JP2010502722A (ja) * | 2006-09-08 | 2010-01-28 | ブレインセルス，インコーポレイティド | ４−アシルアミノピリジン誘導体を含む組み合わせ |
| WO2008036294A2 (en) * | 2006-09-19 | 2008-03-27 | Northwestern University | Nos inhibitors for treatment of motor deficit disorders |
| CA2974689C (en) * | 2007-06-22 | 2020-02-25 | The United States Of America As Represented By The Department Of Veters Affairs | Inhibitors of ncca-atp channels for therapy |
| PE20120791A1 (es) * | 2009-02-11 | 2012-07-08 | Acorda Therapeutics Inc | Composiciones y metodos para terapia prolongada con aminopiridinas |
| JO3348B1 (ar) * | 2009-08-11 | 2019-03-13 | Acorda Therapeutics Inc | استخدام 4- بايريدين امينو لتحسين الادراك العصبي و/او التلف النفسي لدى مرضى يعانون من نقص النُخاعين وغير ذلك من امراض الجهاز العصبي |
-
2012
- 2012-01-27 BR BR112013019265A patent/BR112013019265A2/pt not_active Application Discontinuation
- 2012-01-27 WO PCT/US2012/022960 patent/WO2012103471A1/en not_active Ceased
- 2012-01-27 JP JP2013551380A patent/JP2014503596A/ja not_active Withdrawn
- 2012-01-27 CA CA2825810A patent/CA2825810A1/en not_active Abandoned
- 2012-01-27 EP EP12702948.6A patent/EP2667869A1/en not_active Withdrawn
- 2012-01-27 AU AU2012211101A patent/AU2012211101B2/en not_active Ceased
- 2012-01-27 EP EP15172998.5A patent/EP2995305B1/en active Active
- 2012-01-27 US US13/360,621 patent/US20130030025A1/en not_active Abandoned
-
2016
- 2016-07-04 JP JP2016132185A patent/JP2016222685A/ja active Pending
-
2018
- 2018-07-20 JP JP2018136369A patent/JP2018197242A/ja active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2014503596A5 (enExample) | ||
| HRP20140783T1 (hr) | Uporaba epotilona d u lijeäśenju tau-povezanih bolesti ukljuäśujuä†i alzheimerovu bolest | |
| JP2005537268A5 (enExample) | ||
| CA2492081A1 (en) | Pharmaceutical compositions comprising dextromethorphan and quinidine for the treatment of neurological disorders | |
| EA200800881A1 (ru) | Лекарственная форма пирфенидона в виде капсул с фармацевтически приемлемыми эксципиентами | |
| JP2010523587A5 (enExample) | ||
| FI3668509T3 (fi) | Menetelmä hoitaa amyotrofista lateraaliskleroosia pridopidiinilla | |
| JP2013507352A5 (enExample) | ||
| HRP20220902T3 (hr) | Pripravci i njihova upotreba u liječenju multiple skleroze | |
| JP2010525050A5 (enExample) | ||
| JP2007532663A5 (enExample) | ||
| JP2019524856A5 (enExample) | ||
| JP2001518509A5 (enExample) | ||
| JP2015524444A5 (enExample) | ||
| NZ569331A (en) | COP 1 for treatment of inflammatory bowel diseases | |
| NZ613291A (en) | Treatment of cognitive disorders with (r)-7-chloro-n-(quinuclidin-3-yl)benzo[b]thiophene-2-carboxamide and pharmaceutically acceptable salts thereof | |
| HK1206246A1 (en) | Use of high dose laquinimod for treating multiple sclerosis | |
| ME02474B (me) | Terapijski režimi | |
| JP2013501805A5 (enExample) | ||
| CN102143687A (zh) | 4-氨基吡啶在改善具有脱髓鞘和其它神经系统状况的患者的神经-认知和/或神经-精神病学损伤中的用途 | |
| NO20080244L (no) | Doseringsstyring for prasugrel | |
| US20090149518A1 (en) | Pharmaceutical for protection of motor nerve in patient with amyotrophic lateral sclerosis | |
| JP2015522077A5 (enExample) | ||
| JP2016505050A5 (enExample) | ||
| JP2011500589A5 (enExample) |